Trusted Workflows for High Value Cells

Solentim is the trusted global leader for solutions to create, isolate, and characterize the highest value cells for the development of new biological medicines, including cell and gene therapies, monoclonal antibodies, vaccines and stem cells.

Our customers, which include the world’s leading pharmaceutical and biotherapeutics companies, achieve accelerated development of their master cell banks and are confidently prepared for regulatory review.

NEW ! High Efficiency Single Cell Cloning of iPSCs

Defining a new workflow for clonal iPSC Master Cell Banks

Solentim Products

Instruments and enabling reagents for high efficiency single cell seeding and rapid daily imaging capturing multiple pieces of evidence of clonal derivation, Solentim encapsulates best practice for IND submission.
Read More >

Cell Based Development Workflows

Offering a range of accelerated workflows with built in evidence of clonal derivation for cell line development, viral vector production for gene therapy and vaccine manufacturing.

Read More >

Solentim Insights and News

The latest insights and news for the high value cell community. Includes webinars, podcasts and blogs.

Read More >

On-Line Product Demos

Evaluating Technology at a Distance – register for a range of detailed and immersive on-line activities.

Read More >

NEW WEBINAR

"Establishing New Standards in Efficient Single Cell Cloning of hiPSCs"

Latest News

Solentim Appoints New Non-Executive Director

Solentim are pleased to announce the appointment of Dr Julian Burke as a non-executive Director. A former lecturer in Biochemistry at the University of Sussex, UK, Dr Burke has over

Clonality assurance and the rise of therapeutic monoclonal antibody development

Monoclonal antibodies – a recent history Over three decades ago, in 1986, the first monoclonal antibody (mAb) treatment was approved by the United States Food and Drug Administration (US FDA)[1].

Solentim to launch the ICON™ in 2021

Solentim is happy to announce that its new Cell Line Development platform, the ICON, will launch early 2021. For over a decade, Solentim has provided leading solutions to create, isolate

Is it time for a new standard for the culture of iPSCs?

For those delivering advanced therapy medicinal products, the question of assessing and managing cell population heterogeneity presents an ongoing challenge. Solentim and EverCell Bio addressed this topic at a recent

Solentim to present online at the 9th Cell Line Development & Engineering Asia digital conference

Solentim is happy to announce that it will be presenting at the 9th Cell Line Development & Engineering Asia conference, taking place 3-5 November 2020. This digitally delivered event brings together the

Solentim Cell Metric and VIPS selected by US Government Lab to support latest vaccine research

As part of the concerted fight against COVID-19, the Vaccine Research Center (VRC) at the National Institute for Allergy and Infectious Diseases at the U.S. National Institutes of Health has